440 likes | 961 Views
Diagnosis and Treatment of Multiple Myeloma. Mark B. Juckett MD Division of Hematology University of Wisconsin December 11, 2002. Introduction. Multiple myeloma is a clonal plasma cell neoplasm Usually accompanied by monoclonal antibody production 1% of all cancer Median age 65 years
E N D
Diagnosis and Treatment of Multiple Myeloma Mark B. Juckett MD Division of Hematology University of Wisconsin December 11, 2002
Introduction • Multiple myeloma is a clonal plasma cell neoplasm • Usually accompanied by monoclonal antibody production • 1% of all cancer • Median age 65 years • Incidence higher in African populations
Myeloma Mortality by State 75,075 total deaths 1970 –1994 White males
Myeloma Mortality by State 75,075 total deaths 1970 –1994 Black males
Etiology • Familial clustering • African Americans • Radiation • Agriculture, Benzene, Radiation, Sheet metal work • Chronic inflammatory disorders
Pre B cell IgM B cell Follicles Bone Marrow Lymph Node Normal B cell Development Travel
“meaning” B cell activation Germinal Center Formation B cell finds “meaning”
Memory B cell “Activated B cell” Plasma Cell Plasma Cells travel back to bone marrow
Properties of Plasma Cells • Proliferate • Secrete Immunoglobulins • “Make space” • Influence bone turnover • Secrete Inflammatory mediators
Clinical Manifestations • Plasma Cell proliferation • Pancytopenia, bone damage, constitutional symptoms, anorexia, cachexia, hypercalcemia • Monoclonal protein production • Renal failure, hyperviscosity, amyloidosis, hypoalbuminemia, neurologic symptoms • Immunodeficiency • Infection, autoimmune phenomena
Symptoms Back Pain Fatigue Anorexia Recurrent infection Constipation Somulence Fracture Neuropathy Signs Lytic lesions Anemia, pancytopenia Hypercalcemia Renal insufficiency Monoclonal proteins Organomegaly Bone tumors Hypogammaglobulins Presenting Symptoms and Signs
H&P CBC BUN/creat, lytes Calcium/albumin Quant Ig SPEP/immunofix Bone Marrow Biopsy 24-hour urine UPEP/immunofix Beta2-microglobulin Skeletal survey Initial Diagnostic Workup
Lytic Bone Lesions in Myeloma • Important for diagnosis • Treatment of impending fracture
Stage I (All) Hgb > 10 g/dl Normal calcium Normal bones or Solitary plasmacytoma Low M-protein IgG < 5 g/dl IgA < 3 g/dl Light chains < 4 g/24 h Stage III (Any) Hgb < 10 g/dl Hypercalcemia Multiple lytic lesions High M-protein IgG > 7 g/dl IgA > 5 g/dl Light chains > 12 g/24 h StagingGreater than 20% plasma cells • Stage II – not fitting I or III
Smoldering Myeloma • Monoclonal gammopathy • IgG > 3.5 g/dl and < 5 g/dl • IgA > 2 g/dl and < 3 g/dl • Urine light chains > 1 g/dl • Bone Marrow Plasma cells • Greater than 10% and less than 20% • No anemia, renal insufficiency, hypercalcemia • No lytic lesions or diffuse osteopenia
NCCN Treatment Guidelines • National Comprehensive Cancer Network • Group of NCI Cancer Centers • Evidence based guidelines of appropriate care for general population • Reviewed annually and updated by panel members • Available online: www.nccn.org
TreatmentSolitary Plasmacytoma • Radiation therapy 45 to 50 Gy • Follow up • CBC, SPEP, UPEP, chemistry every 3 months • Bone Survey ± CT scan or MRI every 6 mo • Yearly evaluation after one year and no disease
TreatmentSmoldering or Stage I myeloma • Counseling and observation • Followup • CBC, SPEP, UPEP, chemistry every 3 mo • Bone survey ± Bone marrow biospy every 6 mo • Clinical trial of thalidomide or other biological therapy • Progression to Stage II, III disease • Treat accordingly
Treatment Stage II or III disease • General Goals of Oncology • Cure to regain normal life • Achieve complete remission to preserve quality life • Control disease to preserve quality life • Minimize symptoms • Prevent suffering
Treatment Stage II or III disease • Combination chemotherapy • Not curative, complete remission uncommon • Multiple regimens – none yet shown to improve survival over 30 years of study • Regimen choice depending on goals of therapy • Supportive care crucial for preservation of function and activity
TreatmentStage II or III disease • Goals of initial treatment • Gain control of disease • Improve organ function • Maintain activity & function • Relieve pain, constitutional symptoms • Chemotherapy regimens differ in toxicity, ability to achieve remission • Approach differs depending on age, comorbidity, possibility of stem cell transplant
Stem cell transplant for myeloma • Rationale • Dose response relationship for remission and hematologic toxicity • Stem cell transplant minimizes the hematologic toxicity of high dose chemotherapy • Stem cell transplant has no anti-myeloma effect per se but allows escalation of chemotherapy
Randomized Trials Comparing Standard vs. High-dose chemotherapy
High-dose Chemotherapy for Myeloma • 5 yr OS • Convential chemo 12% • High Dose 52% • No Cure Attal NEJM 335:91, 1996
Candidates for High-dose chemotherapy • Who? • Responding patients • Age < 65 yo, possible for age 65 – 75 years • Adequate renal, pulmonary, cardiac function • When? • Upfront vs. first relapse: Same overall survival, but better QOL with upfront
Investigational Approaches • Thalidomide • Response rate 36% in relapse • PS-341, Arsenic trioxide, R115777 • Allogeneic transplant • Outpatient treatment with minimal chemotherapy • Studies suggest long remissions – Cure?
Non-myeloablative SCT Immuno suppression only Stem cells Manipulate the Immune response to maximize Graft vs. Disease
Auto/Allo Transplant for Myeloma • Auto - improve cytoreduction with less morbidity prior to NST • Allo NST - use in minimal residual disease state to allow time for “GVM” • Separate Auto and Allo to reduce TRM
Auto/Allo NST - Results • 32 patients (median age 55) • Previously treated (43% refractory/relapse) • Mel-200 with PBSCT • NST - TBI 2Gy, PBSCT, CSA, MMF • 31/32 received both • NST - median 0 days hospitalization, neutropenia, thrombocytopenia Maloney, Blood 98:1822a
Auto/Allo NST - Results (cont) • Overall survival 81% (median f/u 423 days) • Day-100 mortality 6% • GVHD • Acute 45% • Chronic 55% • Response Rate 84% (CR 53%, PR 31%) • 2 Patients have progressed Maloney, Blood 98:1822a
Supportive Care • Prevent Fractures • 85% of patients have lytic bone disease • Biphosphonates – Pamidronate, Zolentronate • Local radiotherapy for critical lytic lesions and persistent pain • Anemia • Erythropoietin helpful for anemia patients • Infection • Prophylactic antibiotics and IV immunoglobulin for patients with recurrent infection
Monoclonal Gammopathy • Increasingly common with age • Associated with many inflammatory conditions • Diagnosis depends on finding M-protein • But • No evidence of clinical disease • No lytic lesions • Plasma cells below 10% in the bone marrow • Normal blood counts and renal function
Distinguishing between MGUS and Myeloma • Rising M-spike • Urinary free light chains • Decreased immunoglobulins • Plasmacytosis greater than 10% • Osteolysis • Hypercalcemia • Spleen or liver involvement • Anemia or pancytopenia • Elevated ESR
Conclusions • Myeloma is a cancer of plasma cells • Patients suffer primarily from bone disease, anemia and renal disease • Conventional treatment is non-curative • Aggressive treatment with high-dose chemotherapy preserves quality life • Supportive care improves quality life (and survival)